It mimics the action of the naturally occurring GLP-1 hormone, which stimulates insulin secretion in response to meals, suppresses glucagon release, and slows gastric emptying
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
Some researchers prefer the tirzepatide-tesamorelin combination as a middle ground: more potent than semaglutide-tesamorelin but less experimental than retatrutide-tesamorelin
In contrast, arrestin recruitment to GIPR and its potential consequences are less well understood
Tirzepatide produced up to about 20.9 percent average weight loss at its studied doses over 72 weeks, per the SURMOUNT-1 trial in the New England Journal of Medicine, 2022, and federal health guidance describes obesity as a chronic disease where medication is often continued long term, as outlined by the National Institute of Diabetes and Digestive and Kidney Diseases
A detailed comparison of semaglutide vs metformin for weight loss results highlights this gap
)
